CAMBRIDGE, Mass.--(BUSINESS WIRE)--FoldRx Pharmaceuticals, Inc. (FoldRx) announced today that it has appointed William E. Aliski, as Senior Vice President and Chief Commercial Officer, in anticipation of the commercialization of the company’s lead compound, Fx-1006A. Fx-1006A is being developed as the first therapy for the treatment of rare genetic diseases associated with misfolding of a key protein called transthyretin. Mr. Aliski brings to FoldRx a wealth of experience advancing novel therapies for the treatment of orphan diseases to market.
